Physician profile
Mark A Cohen
NPI 1194785485
$10,466.31
in general payments reported to CMS, 2019-2025
39 companies · $1,587 in 2025
The $1,587 reported for 2025 was more than what 84% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $1,065 · 2021: $1,371 · 2022: $1,860 · 2023: $1,352 · 2024: $2,251 · 2025: $1,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,189.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,586.36 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Novartis Pharmaceuticals Corporation | $1,757.00 | 2019-2025 | |
| Lilly USA, LLC | $773.61 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $527.63 | 2019-2024 | |
| Ucb, INC. | $524.97 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $483.89 | 2019-2024 | Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $377.73 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $371.40 | 2019-2025 | Aklief, Nemluvio |
| Organogenesis INC. | $322.39 | 2020-2024 | |
| Incyte Corporation | $309.84 | 2022-2025 | Opzelura |
| Amgen INC. | $298.77 | 2020-2024 | Otezla |
| Janssen Biotech, INC. | $277.94 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $200.94 | 2021-2025 | Sotyktu |
| Kerecis Limited | $199.11 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Allergan, INC. | $162.22 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.